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ABSTRACT 
Objective: The aim of the study was to find the dual effects of polysorbate-80 concentration on oxidation and aggregation in the formulation of 
granulocyte colony stimulating factor. 
Methods: The effect of polysorbate-80 at different concentration was monitored and analyzed using high performance liquid chromatography. 
Oxidative degradation and aggregate generation was studied using reverse phase and size exclusion chromatography method respectively.  
Results: With increase in concentration of polysorbate-80 the amount of oxidation as well as aggregate formation increases in a concentration 
dependent manner. The aggregates present at higher concentration of polysorbate-80 formulation are not found with low concentration or without 
polysorbate-80. This result shows that higher concentration of Tween-80 force the formation of oligomers and leads to increased level of oxidation 
of granulocyte colony stimulating factor. 
Conclusion: The dual effect of aggregation and oxidation of polysorbate-80 on the recombinant granulocyte colony stimulating factor indicate that 
during formulation development studies it is crucial to evaluate the amount of polysorbate-80 to be used in the formulation. 
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INTRODUCTION 
Granulocyte colony stimulating factor (G-CSF) or colony stimulating 
factor, a cytokine that is produced by macrophages that induce 
proliferation of neutrophil colonies and differentiation of precursor 
cells to neutrophils (1). They are responsible for detecting and 
destroying harmful bacteria and some fungi. The G-CSF is being used 
for more than two decades to treat congenital and acquired 
neutropenia and to reduce febrile neutropenia before or during 
courses of intensive cytoreductive therapy (2). G-CSF is used as 
medications to stimulate production of infection fighting white 
blood cells (WBCs), febrile neutropenia (3). 
Polysorbates are the most extensively used non-ionic surfactants in 
biopharmaceuticals to stabilize proteins to prevent aggregation (4), 
minimize surface absorption of proteins (5,6) and withstand various 
stresses like shaking (7), freeze thawing (8) and lyophilization 
(9,10). However some of their effects on protein formulation need to 
be examined in more details. The most commonly used non-ionic 
surfactants are Tween 20 (Polysorbate 20) and Tween 80 
(Polysorbate-80). Beside these Triton X-100, Pluronic F-68, Pluronic 
F-88, Pluronic F-127 (poloxamers) (11-12) and Brij 35 
(polyoxyethylene alkyl ether) are also used. It is estimated that 70 % 
of monoclonal antibody biotherapeutics uses polysorbate-80 (13). 
 Biotherapeutic protein like monoclonal antibody also has a 
tendency to form aggregates. There are more than 30 monoclonal 
antibodies (MABs) marketed in United States and Europe. In 2010, 
the US only has sales of 18.5 billion dollar which is expected to 
continue at a combined annual growth rate (CAGR) > 10% (37). 
The general process involved during manufacturing of 
biopharmaceuticals like filtrations (14), pumping (15), shaking or 
stirring (8), freeze thawing (16) may lead to generation of 
aggregates (17). Aggregation has a number of deleterious effects on 
biotherapeutics including the loss of efficacy (18), induction of 
unwanted immunogenicity (19), altered pharmacokinetics (20) and 
reduced shelf life. Aggregation is ameliorated by the inclusion of 
surfactants in biotherapeutic formulations, typically non-ionic 
polymeric ether surfactants. The generation of aggregates may lead 
to loss of yield and increase in manufacturing cost. Even the small 
percentage of generation of aggregates may alter the 
pharmacokinetic or pharmacodynamic profile of the drug by 
reducing bioavailability and finally the efficacy. The most serious 
problem is the induction of unwanted immunogenicity response 
thereby decreasing the efficacy as in “pure red-cell aplasia” during 
treatment with erythropoietin (20), neutralizing antibodies against 
interferon beta led to higher relapse rate and more disease activity 
(18,21). 
Polysorbates contain low levels of residual peroxides, which may 
accumulate during storage and cause instant or long-term damage to 
the active biopharmaceutical ingredients (22, 23). Polysorbates are 
known to be degraded by auto-oxidation and hydrolysis yielding 
reactive peroxides (22, 24). The presence of residual levels of 
peroxide in bulk polysorbate is also important. The European 
Pharmacopeia has specified a limit of peroxide number (PN) ≤ 10  
(25). The oxidative damaging effect of peroxides in surfactants on 
drug molecules has been extensively reported (26-28). The main 
sites of oxidation within proteins are the methionine and tryptophan 
residues (29-30). The problem of immunogenicity is aggravated 
when both oxidation and aggregation takes place simultaneously 
(31). The dual effect of aggregation and oxidation on protein 
stability of polysorbate-80 has been reported, eg. IL-2 (32). 
The main objective of our present study was to check the dual effect 
of Tween-80 concentration upon oxidation and aggregation on G-
CSF drug formulation. Size Exclusion High Performance Liquid 
Chromatography (SE-HPLC) was utilized to study the generation of 
aggregates while Reverse Phase High Performance Liquid 
Chromatography (RP-HPLC) was utilized for detection of oxidized 
impurity. 
MATERIALS AND METHODS 
Sample preparation 
The stock solution of polysorbate-80 (60 mg/ml) was prepared in G-
CSF formulation buffer. From this stock, different concentration of G-
CSF containing 0.04%, 0.1% and 0.2% polysorbate-80 was prepared. 
Final concentration of G-CSF was ≈ 0.79 mg/ml in formulation 
buffer. All samples were incubated for 36 h at room temperature.  
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High-performance liquid chromatography 
The analytes were separated using a Waters 1525 HPLC system 
(Waters Corporation Milford, MA, USA). The columns used for SEC 
was TSK-GEL 3000 SWxl (7.8 mm and 30 cm; 10 µm particle size). 
Different mobile phase buffer and conditions were tested to 
eliminate the chances of any contribution of buffer in the formation 
of oligomer. Initially mobile phase used were phosphate buffer (pH- 
6.9) having KH2PO4 (2 mM), Na2HPO4 (3 mM), NaCl (110 mM) 
containing 10 % methanol. The flow rate was maintained at 0.5 
ml/min with a run time of 30 min. The detector was set at a 
wavelength 215 nm. The second mobile phase used was ammonium 
bicarbonate (0.395%-pH-7.0). 
For RP-HPLC Grace Vydac C18 reverse phase column were used (4.6 
X 25 cm, 300Å, 5 µm particle size). A linear gradient program was 
applied as follows: 0-5 min: 25% B; 5-8 min: 40% B; 8-12 min: 46% 
B; 12-37 min: 66% B; 37-50: 80% B; 50-52 min/;100 %B; 52-54 
min: 25% B; 54-60 min: 25 % B. The flow rate was maintained at 0.8 
ml/min and the temperature of the column was set at 60º C. The 
detector was set at 214 nm with a run time of 60 min. The binary 
mobile phase consisted of (A) water and (B) acetonitrile containing 
0.1% trifluoroacetic acid. All the chemicals were of analytical grade 
purchased from Merck and Sigma (USA). 
RESULTS AND DISCUSSION  
RP-HPLC 
The reverse phase HPLC was performed using Grace Vydac C18 
column with 0.1% TFA in Acetonitrile and Water.  
 
 
Fig. 1: Overlay chromatogram of RP-HPLC of drug product with 
different concentration of Polysorbate-80. The amount of 
oxidation as well as post peak impurity of G-CSF increases with 
respect to polysorbate-80 concentration. 
 
A decrease in retention time of the protein was observed upon 
oxidation. It was also observed that with increase in the 
concentration of polysorbate-80, the amount of oxidation also 
increases in a concentration dependent manner as shown through 
overlay of chromatograms (Fig. 1). Not only the oxidation but the 
amount of post peak impurities also increases with respect to 
increase in polysorbates concentration (Fig. 1). 
Size exclusion Chromatography 
Size Exclusion chromatography was performed to analyze the effect 
of polysorbate-80 concentration using a TSK- GEL 3000 SWxl 
column. The overlay of SEC chromatograms showed that as the 
concentration of polysorbate-80 was increased the amount of 
aggregates also increased. Significant variation has been observed in 
the SE-HPLC chromatogram of sample with low concentration or 
without polysorbate-80 as compared to higher concentration. The 
aggregates or oligomer present at high concentration of 
polysorbate-80 is not found to be generated in sample with 0.004% 
polysorbate-80 and without polysorbate-80; rather only dimer 
formation is occurred (Table 1, Fig. 2).  
The dimer had a retention time of 20 min whereas oligomer had 16 
min. This result showed that higher concentration of polysorbate-80 
force the formation of oligomer. The HP-SEC buffers were modified 
in order to check that if there is any effect of the buffer in formation 
of oligomer. Ammonium bicarbonate at pH 7.0 was used as (mobile 
phase). The overlay of chromatogram (Fig. 3) showed that as the 
concentration of polysorbate-80 increased the amount of aggregate 
also increased suggesting buffer, component has no role in 
generation of aggregate. 
 
 
Fig. 2: Overlay SE-HPLC Chromatogram showing that as the 
concentration of Tween-80 increases the amount of aggregate 
increases. The aggregates or oligomer present at high 
concentration of polysorbate-80 is not found to be generated in 
sample with 0.004% polysorbate-80 and without polysorbate-
80 rather only dimer formation is favored.
 
Table 1: Shows the retention time of peak of RP-HPLC and SE-HPLC 
S. No. Polysorbate concentration RP-HPLC Rt (min.) SEC Rt (min.) 
Principal pk Oxidized pk Principal pk Aggregate pk Oligomer pk 
1 0.0 % 37.5 35.0 22.0 19.8 Not detected 
2 0.004 % 37.5 35.25 22.0 19.8 Not detected 
3 0.04 % 37.5 35.25 22.0 19.8 16.0 
4 0.1 % 37.5 35.25 22.0 19.8 16.0 
5 0.2 % 37.5 35.25 22.0 19.8 16.0 
 
Surfactants are essential components of many biotherapeutic 
formulations. They may induce unwanted immunogenicity by 
generation of aggregated and oxidized forms of proteins. 
Polysorbates are effective in preventing protein aggregation, but 
they contain ether linkages and polysorbate-80 has unsaturated 
alkyl chains that spontaneously auto oxidize in aqueous solution to 
produce damaging peroxides, epoxy acids and reactive aldehydes 
(25). Degradation of polysorbates decreases its ability to protect the 
formulation and the degraded molecules damage the protein 
stability.  
The peroxide generated cause oxidation of proteins and aldehyde 
induces unwanted immunogenicity in proteins by reaggregating 
proteins (22, 34). The types of aggregate vary in size and differ 
according to the nature of the protein, like it may be soluble, 
insoluble, covalent or non-covalent, reversible or irreversible. 
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In our study the dual effects of polysorbate-80 concentration on 
aggregation and oxidation on G-CSF has been observed which is the 
most serious problem associated with the biosimilar drugs. The 
result obtained shows that aggregate formation is favored by the 
partially unfolded structure of protein, since polysorbate-80 is a 
detergent and its high concentration causes structural change which 
favor the formation of aggregate. The high concentration of 
polysorbates generates more amount of peroxide which led to not 
only oxidation of G-CSF but also to post peak impurity. There are 
damaging effects of polysorbate on proteins even if the 
concentration is less, which is not observed immediately, 
immunogenicity may arise only after repeated administration over 
an extended period or use of higher doses. So the damaging effect of 
all potential source of unwanted immunogenicity of biotherapeutics 
must be dealt with strong risk management. Therefore, proper 
planning is essential for development of new drug to make sure it is 
safe, reliable and stable. 
 
 
Fig. 3: Overlay SE-HPLC Chromatogram showing the increase in 
amount of aggregate on increasing concentration of Polysorbate-80 
when using ammonium carbonate as mobile phase. 
 
Polysorbate produces reactive species which cause chemical 
modification of aminoacyl side chains of proteins producing a non-
similar molecule which can lead to immune response and 
subsequently generate antibodies against the drug in use. This 
creates a technical challenge for manufacturer of biosimilars where 
it is required to demonstrate not only the similarity of the drug but 
also the similarity of impurities of excipients. 
Due to the severe nature and problems coupled with the 
development of unwanted immunogenicity of the biotherapeutics, 
the Food Drug and Administration with European Medicinal 
Agencies has highlighted their concern regarding aggregation in its 
new guidelines (35). The Committee for Medicinal Products for 
Human Use (CHMP) in 2009 at the European Medicines Agency 
issued marketing authorization guidelines for general 
recommendations on how to assess an unwanted immune response 
following the administration of a biotherapeutic drug (36). The 
evaluation of the equivalence of different excipients for the 
stabilization of biotherapeutic has not been well defined which may 
be included in future.  
Most studies carried out on the use of polysorbate have looked on 
the avoidance of aggregation for reducing immunogenicity. While 
oxidative damage to protein on storage has to be included in future 
studies by modifiing aminoacyl groups in a biotherapeutic during 
stability analysis rather than to measure the reactive contaminants 
(like peroxide) in final product. Although “High purity” polysorbates 
are commercially available having head space filled with inert gas 
like nitrogen or argon, but as soon as it comes in contact with 
oxygen oxidation starts.  
CONCLUSION 
In this present work we have demonstrated the dual effect of 
aggregation and oxidation of polysorbate or Tween-80 on the 
recombinant G-CSF. The formation of aggregates and oxidized 
species are a concern when using polysorbates in formulation of 
biotherapeutics. Alternative surfactant must be tried in future to 
prevent aggregation and oxidation of biotherapeutics. 
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